Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Laboratoires CTRS

- PMLiVE

AstraZeneca’s Forxiga shows promise in paediatric type 2 diabetes trial

The prevalence of type 2 diabetes in children and adolescents is increasing globally

- PMLiVE

Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn

About ten million people worldwide are affected by inflammatory bowel disease

- PMLiVE

Sanofi enters agreement with Janssen to develop E. coli vaccine candidate

Extraintestinal pathogenic E. coli is a leading cause of sepsis, particularly in older adults

- PMLiVE

Further data for AstraZeneca/Daichii Sankyo’s Enhertu requested by NICE

Enhertu is currently approved for HER2-low metastatic breast cancer in over 30 countries

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study

More than two million people worldwide are diagnosed with breast cancer every year

- PMLiVE

Sanofi and Ad Scientiam partner to assess MS disability progression

The study will evaluate the ability of MSCopilot to identify early signs of disability worsening

- PMLiVE

AstraZeneca’s rare disease unit partners with Verge Genomics in deal worth over $840m

Both will identify drug targets for neurodegenerative and neuromuscular diseases

- PMLiVE

AstraZeneca shares positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine recommended by CHMP

Doses will be ready to ship immediately upon authorisation by the European Commission

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

AstraZeneca latest to sue US government over Medicare drug price negotiation plan

The programme already faces court challenges from drugmakers and industry groups

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by CDC advisory committee for infants

Beyfortus will be available in the US ahead of the upcoming RSV season

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links